MicroRNA‐184 and its lncRNA sponge uca1 are induced in wounded keratinocytes in a store‐operated calcium entry‐dependent manner

Abstract

There remains a significant need for therapeutic interventions for wound healing as the clinical and socioeconomic challenges presented by the ageing population and associated rise in non‐healing wounds persist, exerting enormous pressure on health services. MicroRNAs (miRNAs) are short ≈22 nucleotide non‐coding RNA molecules that fine‐tune gene expression by degradation of mRNA targets. Several miRNAs promote keratinocyte migration, including miR‐21, miR‐31 and miR‐132 (reviewed in ³), hence miRNA‐dependent migration is emerging as a framework for wound healing.

This article is protected by copyright. All rights reserved.

http://bit.ly/2EXbxfA

Substantially reduced life expectancy in patients with hidradenitis suppurativa: A Finnish nationwide registry study

Abstract

Hidradenitis suppurativa (HS) is associated with severe comorbidities,^1,2 but has not previously been subject to a systematic evaluation of mortality risk. We conducted a retrospective registry‐based case‐control study to describe life expectancy and cause‐specific death risks in patients with HS.

This article is protected by copyright. All rights reserved.

http://bit.ly/2EYpcDV

“Invasive Proliferative Gelatinous Mass” of Hidradenitis Suppurativa contains distinct inflammatory components

Abstract

As defined by the European Dermatology Forum, Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin disease of the hair follicle in the axillae, inguinal and anogenital regions (Fig 1a, top). For severe cases, surgical management of lesions by "deroofing" is helpful. As first described by William Danby, sinus tracts contain an "invasive proliferative gelatinous mass (IPGM)" attached to the sinus tract epithelium[1]. However, the components of IPGM have not been investigated. We used existing, de‐identified, un‐matched samples of IPGM, serum and skin biopsies from normal subjects, HS patients, and acne patients to compare the composition of immune cells and cytokines all in an effort to understand the magnitude and potential biological impact of IPGM within HS lesions.

This article is protected by copyright. All rights reserved.

http://bit.ly/2EVcW6i

Misuse of veterinary wormers in self‐medication of rosacea and scabies

Abstract

Dermatology patients are increasingly well informed about chronic skin conditions such as rosacea. Online forums are a popular way for patients to discuss treatments ranging from prescription drugs to alternative medicines. The introduction of topical ivermectin 1% has recently gained traction in these forums. We report a patient with papulopustular rosacea who had an excellent response to topical ivermectin 1% cream.

This article is protected by copyright. All rights reserved.

http://bit.ly/2EZ93hO

Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis

Abstract

Higher rates of conjunctivitis have been reported in atopic dermatitis (AD) patients treated with dupilumab, an anti‐interleukin (IL)‐4Rα antibody inhibiting IL‐4 and IL‐13, compared to patients treated with placebo.¹ However, the exact pathomechanism has not been clarified. Given the necessity of optimal treatment and risk management, the aim of this study was to describe the histopathological characteristics of conjunctivitis during dupilumab treatment in AD patients.

This article is protected by copyright. All rights reserved.

http://bit.ly/2EZw9nl

The Novel Mevalonate Kinase Mutations Cause Disseminated Superficial Actinic Porokeratosis

Abstract

Disseminated superficial actinic porokeratosis (DSAP) is a rare autosomal dominant disease. In our previous research, we found that a linkage region of DSAP in a large family is located at 12q23.2‐q24.1. Subsequently, mevalonate kinase (MVK) gene was proved as a pathogenic gene of DSAP. Here, we report a new missense mutation c.566 C> T (p.A189V) in MVK in a Chinese DSAP pedigree. Mechanically, we demonstrate that both pathogenic p.A189V mutant and a sporadic mutation p.H312R(c.935A>G) which we reported previously have rapid degradation, decreased kinase activity and reduced production of cell cholesterol. Meanwhile, we found p.H312R mutation make MVK inability to form dimers. Furthermore, we demonstrate that the mutants are impaired in mitochondrial function and lead to increased apoptosis. Our results provide an important basis for elucidating the mechanism by which MVK missense mutations contribute to DSAP.

This article is protected by copyright. All rights reserved.

http://bit.ly/2EZeeOD

Factors influencing current low‐value follow‐up care after basal cell carcinoma and suggested strategies for de‐adoption: a qualitative study

Summary

Background

Providing follow‐up to low‐risk basal cell carcinoma (BCC) patients can be considered as low‐value care. However, dermatologists still provide substantial follow‐up care to this patient group, for reasons not well understood.

Objectives

The aim of this study was to identify factors influencing current BCC follow‐up practices among dermatologists and suggested strategies to de‐adopt this low‐value care. In addition, views of patients regarding follow‐up care were explored.

Methods

A qualitative study was conducted consisting of 18 semi‐structured interviews with dermatologists and three focus groups with a total of 17 low‐risk BCC‐patients who had received dermatological care. The interviews focused on current follow‐up practices, influencing factors, and suggested strategies to de‐adopt the follow‐up care. The focus groups comprised preferred follow‐up schedules and providers as well as content of follow‐up. All (group)interviews were transcribed verbatim, and analysed by two researchers using Atlas.ti software.

Results

Factors influencing current follow‐up care practices among dermatologists included complying with patients' preferences, lack of trust in general practitioners (GPs), financial incentives and force of habit. Patients reported varying needs regarding periodic follow‐up visits, preferred to be seen by a dermatologist and indicated a need for improved information provision. Suggested strategies by dermatologists to de‐adopt the low‐value care encompassed educating patients with improved information, educating GPs to increase trust of dermatologists, realising appropriate financial reimbursement and informing dermatologists about the low‐value of care.

Conclusions

A mixture of factors appear to contribute to current follow‐up practices after low‐risk BCC. In order to de‐adopt this low‐value care, strategies should be aimed at dermatologists, GPs as well as patients.

This article is protected by copyright. All rights reserved.

http://bit.ly/2EVtZFv